Regeneron Pharmaceuticals Inc
REGN
Key stats
- Open
- 972.30
- Day high
- 981.55
- Day low
- 944.71
- Previous close
- 959.41
- Volume
- 1.21M
- VWAP
- 954.93
- 52-week high
- 991.73
- 52-week low
- 591.52
- Market cap
- 99.25B
- Shares out
- 101.63M
- Employees
- 15,410
- Listed
- 1991
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
PHARMACEUTICAL PREPARATIONS · TARRYTOWN, NY · regeneron.com
Options · expiring Nov 13
Nov 12, 4:00 PM ET- Call open interest
- 386
- Put open interest
- 487
- Put/call
- 1.26
- At-the-money IV
- 42.6%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 895 put | 0.62 | Nov 11, 3:22 PM | 87 | 160 | 72.9% |
| 920 call | 38.00 | Nov 11, 2:54 PM | 70 | 28 | — |
| 955 put | 12.60 | Nov 11, 3:26 PM | 46 | 18 | 46.5% |
| 920 put | 0.70 | Nov 12, 1:07 PM | 27 | 3 | 62.3% |
| 865 put | 2.25 | Nov 9, 11:59 AM | 14 | 15 | 159.2% |
| 880 call | 3.40 | Oct 7, 12:47 PM | 12 | 8 | — |
Quarterly results
Massive · Oct 30, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $5.12B | $4.29B | $3.61B | $3.88B |
| Gross profit | $4.54B | $3.71B | $2.94B | $3.30B |
| Operating income | $2.05B | $1.29B | $642.90M | $869.90M |
| Net income | $1.95B | $1.30B | $727.20M | $844.60M |
| Diluted EPS | 18.45 | 12.23 | 6.75 | 7.86 |
| Operating cash flow | $1.78B | $813.00M | $1.08B | $1.17B |
| Assets | $44.41B | $41.73B | $40.87B | $40.56B |
| Liabilities | $10.91B | $10.02B | $9.45B | $9.30B |
| Equity | $33.50B | $31.71B | $31.42B | $31.26B |
Technicals
Massive · Nov 12, 2026- 50-day average813.93
- 200-day average745.87
- RSI (14 days)67.7
Short interest
Massive · Oct 30, 2026- Oct 30, 20262.22M shares · 2.7 days to cover
- Oct 15, 20262.13M shares · 3.2 days to cover
- Sep 30, 20262.15M shares · 2.5 days to cover
- Sep 15, 20262.53M shares · 4.4 days to cover
Dividends
Massive · Nov 20, 2026- Ex Nov 20, 2026, paid Dec 3, 20260.9400 · 4 a year
- Ex Aug 18, 2026, paid Aug 31, 20260.9400 · 4 a year
- Ex May 20, 2026, paid Jun 4, 20260.9400 · 4 a year
- Ex Feb 20, 2026, paid Mar 5, 20260.9400 · 4 a year
- Ex Nov 20, 2025, paid Dec 5, 20250.8800 · 4 a year
- Ex Aug 18, 2025, paid Sep 3, 20250.8800 · 4 a year
- Ex May 20, 2025, paid Jun 6, 20250.8800 · 4 a year
- Ex Feb 20, 2025, paid Mar 20, 20250.8800
Related companies
MassiveNews coverage
No stories about Regeneron Pharmaceuticals Inc right now.